Marja Hedman

3.4k total citations
78 papers, 2.4k citations indexed

About

Marja Hedman is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Marja Hedman has authored 78 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Cardiology and Cardiovascular Medicine, 25 papers in Pulmonary and Respiratory Medicine and 16 papers in Molecular Biology. Recurrent topics in Marja Hedman's work include Aortic Disease and Treatment Approaches (15 papers), Cardiac Imaging and Diagnostics (14 papers) and Aortic aneurysm repair treatments (13 papers). Marja Hedman is often cited by papers focused on Aortic Disease and Treatment Approaches (15 papers), Cardiac Imaging and Diagnostics (14 papers) and Aortic aneurysm repair treatments (13 papers). Marja Hedman collaborates with scholars based in Finland, Sweden and Denmark. Marja Hedman's co-authors include Seppo Ylä‐Herttuala, Kimmo Mäkinen, Hanna Mussalo, Juha Hartikainen, Antti Hedman, Hannu Manninen, Ritva Vanninen, Pekka J. Matsi, Esko Alhava and Antti Kivelä and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and PLoS ONE.

In The Last Decade

Marja Hedman

72 papers receiving 2.3k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Marja Hedman 1.3k 643 640 336 300 78 2.4k
Mercè Roqué 826 0.6× 880 1.4× 831 1.3× 131 0.4× 197 0.7× 72 2.9k
Kensuke Ohta 676 0.5× 933 1.5× 492 0.8× 150 0.4× 398 1.3× 104 2.7k
Kiyotake Ishikawa 1.9k 1.5× 1.7k 2.6× 864 1.4× 502 1.5× 184 0.6× 128 3.8k
Atsushi Izawa 1.1k 0.8× 912 1.4× 761 1.2× 95 0.3× 255 0.8× 104 2.8k
Kou‐Gi Shyu 1.2k 0.9× 715 1.1× 581 0.9× 132 0.4× 163 0.5× 99 2.5k
Mutsuo Harada 1.2k 0.9× 954 1.5× 405 0.6× 156 0.5× 182 0.6× 34 2.3k
Uta Kunter 1.1k 0.9× 227 0.4× 640 1.0× 173 0.5× 245 0.8× 49 3.0k
Mark D. Rekhter 987 0.8× 384 0.6× 638 1.0× 179 0.5× 157 0.5× 48 2.6k
Masashi Arai 1.5k 1.1× 1.2k 1.9× 275 0.4× 284 0.8× 234 0.8× 76 2.9k
Robert F. Hoyt 926 0.7× 644 1.0× 1.8k 2.7× 498 1.5× 303 1.0× 57 3.4k

Countries citing papers authored by Marja Hedman

Since Specialization
Citations

This map shows the geographic impact of Marja Hedman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marja Hedman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marja Hedman more than expected).

Fields of papers citing papers by Marja Hedman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marja Hedman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marja Hedman. The network helps show where Marja Hedman may publish in the future.

Co-authorship network of co-authors of Marja Hedman

This figure shows the co-authorship network connecting the top 25 collaborators of Marja Hedman. A scholar is included among the top collaborators of Marja Hedman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marja Hedman. Marja Hedman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Laitinen, Tiina M., et al.. (2024). Heparin does not improve myocardial glucose metabolism suppression in [18 F]FDG PET/CT in patients with low β-hydroxybutyrate level. EJNMMI Research. 14(1). 92–92. 1 indexed citations
3.
Hedman, Marja, et al.. (2023). Twenty years’ experience of type B aortic dissections: a population-based national registry study from Finland. Interdisciplinary CardioVascular and Thoracic Surgery. 37(5).
4.
Valtola, Kati, Marja Hedman, Ilkka Kantola, et al.. (2023). Late-onset and classic phenotypes of Fabry disease in males with the GLA-Thr410Ala mutation. Open Heart. 10(1). e002251–e002251. 6 indexed citations
5.
Salomaa, E.-R., et al.. (2023). Ascending aortic length associates to acute aortic dissection. European Heart Journal. 44(Supplement_2).
6.
Husso, Annastiina, et al.. (2022). Reversible myocardial ischaemia caused by ectopic left circumflex coronary artery: a case report. European Heart Journal - Case Reports. 6(4). ytac171–ytac171. 1 indexed citations
7.
Prescott, Eva, Oskar Angerås, David Erlinge, et al.. (2022). Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study. International Journal of Cardiology. 365. 34–40. 8 indexed citations
8.
Kauhanen, Petteri, et al.. (2022). Dilatation of the ascending aorta – Growth rate, risk factors and clinical outcomes in the long-term follow-up. European Journal of Radiology. 150. 110234–110234. 6 indexed citations
9.
Prescott, Eva, Oskar Angerås, David Erlinge, et al.. (2021). EFFICACY, SAFETY AND TOLERABILITY OF THE 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR AZD5718 IN PATIENTS WITH RECENT MYOCARDIAL INFARCTION: A PHASE 2A STUDY (FLAVOUR). Journal of the American College of Cardiology. 77(18). 136–136. 1 indexed citations
10.
Prescott, Eva, John Pernow, Antti Saraste, et al.. (2020). Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction. Contemporary Clinical Trials Communications. 19. 100629–100629. 9 indexed citations
11.
Valtola, Kati, Marja Hedman, Tomi Laitinen, et al.. (2020). Cardiomyopathy associated with the Ala143Thr variant of the α-galactosidase A gene. Heart. 106(8). 609–615. 19 indexed citations
12.
Hämäläinen, H., Tiina M. Laitinen, Marja Hedman, et al.. (2020). Myocardial ischemia and previous infarction contribute to left ventricular dyssynchrony in patients with coronary artery disease. Journal of Nuclear Cardiology. 28(6). 3010–3020. 7 indexed citations
13.
Saari, Petri, et al.. (2019). High prevalence of ascending aortic dilatation in a consecutive coronary CT angiography patient population. European Radiology. 30(2). 1079–1087. 10 indexed citations
14.
Mustonen, Pirjo, et al.. (2018). Left atrial appendage morphology and relative contrast agent concentration in patients undergoing coronary artery CTA. Clinical Radiology. 73(11). 982.e17–982.e26. 4 indexed citations
15.
Taina, Mikko, Ritva Vanninen, Petri Sipola, et al.. (2016). Cardiac CT Differentiates Left Atrial Appendage Thrombi from Circulatory Stasis in Acute Stroke Patients.. PubMed. 30(5). 671–6. 8 indexed citations
16.
Merentie, Mari, Jenni Huusko, Marta Mendel, et al.. (2015). Efficacy and safety of myocardial gene transfer of adenovirus, adeno-associated virus and lentivirus vectors in the mouse heart. Gene Therapy. 23(3). 296–305. 43 indexed citations
17.
Taina, Mikko, Petri Sipola, Antti Muuronen, et al.. (2014). Determinants of Left Atrial Appendage Volume in Stroke Patients without Chronic Atrial Fibrillation. PLoS ONE. 9(3). e90903–e90903. 6 indexed citations
18.
Mäkinen, Kimmo, et al.. (2011). 10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb. Gene Therapy. 19(4). 392–395. 61 indexed citations
19.
Bhardwaj, Shalini, Terhi Kärpänen, Suvi Jauhiainen, et al.. (2005). Periadventitial angiopoietin-1 gene transfer induces angiogenesis in rabbit carotid arteries. Gene Therapy. 12(5). 388–394. 12 indexed citations
20.
Hedman, Marja. (2003). Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. Clinical Pharmacology & Therapeutics. 74(2). 178–185. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mercè Roqué Breakdown of academic impact, for papers by Kensuke Ohta Breakdown of academic impact, for papers by Kiyotake Ishikawa Breakdown of academic impact, for papers by Atsushi Izawa Breakdown of academic impact, for papers by Kou‐Gi Shyu Breakdown of academic impact, for papers by Mutsuo Harada Breakdown of academic impact, for papers by Uta Kunter Breakdown of academic impact, for papers by Mark D. Rekhter Breakdown of academic impact, for papers by Masashi Arai Breakdown of academic impact, for papers by Robert F. Hoyt
Rankless by CCL
2026